Comparison · NCT00035932-b425708f
ATV 300 mg / RTV vs LPV / RTV: Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 96
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ATV 300 mg / RTV vs LPV / RTV: Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 96. Trial comparisons, record NCT00035932-b425708f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00035932-b425708f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.508 | 0.42 | 0.596 | wilson | |
| Risk in group 2 | 0.504 | 0.414 | 0.595 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00391 | -0.123 | 0.13 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.782 | 1.3 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.608 | 1.7 | log | |
| Number needed to treat, for one more participant with the outcome on ATV 300 mg / RTV than on LPV / RTV | 256 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ATV 300 mg / RTV | ATV 300 mg + RTV 100 mg + TDF 300 mg + nucleoside of choice~ATV , RTV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study | 61 | 120 | OG000 |
| Group 2 | LPV / RTV | LPV/RTV 400/100 mg + TDF 300 mg + nucleoside of choice~LPV/RTV twice daily, TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study | 57 | 113 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Participants Achieving Virologic Half Log Suppression (LOQ = 50 c/mL) at Week 96
- Description
- Time frame
- Week 96
- Population
- Randomized participants while on initial regimen (completers censored).
Source ClinicalTrials.gov
Trial
- Title
- Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
- NCT number
- NCT00035932
- Phases
- PHASE3
- Conditions
- HIV Infections
- Interventions
- Atazanavir + ritonavir + tenofovir + nucleoside, Atazanavir + saquinavir + tenofovir + nucleoside, Lopinavir/ritonavir + tenofovir + nucleoside
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2010-12-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00035932?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00035932-b425708f